Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Language
Publication year range
1.
Semergen ; 49(7): 102030, 2023 Oct.
Article in Spanish | MEDLINE | ID: mdl-37487423

ABSTRACT

Venous thromboembolic disease (VTE) is a frequent complication in patients diagnosed with cancer and a cause of morbidity and mortality. Approximately 20% of thromboembolic episodes develop in association with active cancer. On the other hand, it is estimated that about 2-12% of cases, the thromboembolic episode is the first manifestation of an occult cancer, diagnosed at that time or subsequently, which offers an opportunity for early diagnosis and treatment. There are multiple factors that contribute to increase the risk of VTE in oncological patients in relation to specific characteristics of the patient, the tumor and the treatments. Knowledge of these risk factors will contribute to early diagnosis when signs of VTE appear, as well as the assessment of thromboprophylaxis if indicated. The diagnosis of VTE in patients with cancer does not differ of those who do not suffer from it. Regarding the treatment of VTE in these patients, low molecular weight heparin (LMWH), direct acting anticoagulants (DACs) and antivitamin K (VKA) are the most commonly used, although the dosing regimen and length are not clear yet. The management of these patients should be interdisciplinary and early, so the primary care physician plays a key role in this process as he/she is liaise with his/her patients. It is also necessary to update knowledge in order to improve the care of these patients. For these reasons, this document has been prepared by the Working Group on Vasculopathies of the Spanish Society of Primary Care Physicians (SEMERGEN) whose objective is to present the available information regarding the management of VTE that may appear in oncological patients, as well as the assessment of thromboprophylaxis and treatment, if appropriate, from an approach focused on a primary care field.


Subject(s)
Neoplasms , Venous Thromboembolism , Humans , Female , Male , Anticoagulants/therapeutic use , Heparin, Low-Molecular-Weight/therapeutic use , Venous Thromboembolism/diagnosis , Venous Thromboembolism/etiology , Venous Thromboembolism/prevention & control , Neoplasms/complications , Neoplasms/drug therapy , Primary Health Care
2.
SEMERGEN, Soc. Esp. Med. Rural Gen. (Ed. Impr.) ; 48(5): 344-355, Jul. - Ago. 2022. ilus, tab
Article in Spanish | IBECS | ID: ibc-205251

ABSTRACT

La enfermedad venosa crónica (EVC) es la enfermedad vascular más frecuente en el ser humano y sigue siendo infradiagnosticada e infratratada en todos los niveles asistenciales. Los nuevos tiempos que vivimos suponen un aumento de la incertidumbre entre los pacientes crónicos sobre su diagnóstico, tratamiento y seguimiento por parte de los médicos de familia y especialmente en la EVC. Con el fin de abordar estos nuevos tiempos, el Grupo de Vasculopatías de Semergen ha diseñado el cuestionario Venocheck, que valora aspectos etiológicos, clínicos (clasificación CEAP), de severidad y calidad de vida, terapéuticos, presencia de complicaciones y criterios de derivación (AU)


Chronic venous disease (CVD) is the most common vascular disease in humans and continues to be underdiagnosed and undertreated at all levels of care. The new times we live in have led to an increase in uncertainty among chronic patients about their diagnosis, treatment and follow-up by family doctors and especially in CVD. In order to analyze these new times, the Semergen Vasculopathies Group has created the Venocheck questionnaire, which assesses aetiological, clinical (CEAP classification), severity and quality of life, therapeutic aspects, presence of complications and referral criteria (AU)


Subject(s)
Humans , Vascular Diseases/diagnosis , Vascular Diseases/therapy , Venous Insufficiency/diagnosis , Venous Insufficiency/therapy , Surveys and Questionnaires , Chronic Disease , Risk Factors , Quality of Life
3.
Semergen ; 48(5): 344-355, 2022.
Article in Spanish | MEDLINE | ID: mdl-35618620

ABSTRACT

Chronic venous disease (CVD) is the most common vascular disease in humans and continues to be underdiagnosed and undertreated at all levels of care. The new times we live in have led to an increase in uncertainty among chronic patients about their diagnosis, treatment and follow-up by family doctors and especially in CVD. In order to analyze these new times, the Semergen Vasculopathies Group has created the Venocheck questionnaire, which assesses aetiological, clinical (CEAP classification), severity and quality of life, therapeutic aspects, presence of complications and referral criteria.


Subject(s)
Vascular Diseases , Venous Insufficiency , Chronic Disease , Humans , Quality of Life , Vascular Diseases/diagnosis , Vascular Diseases/epidemiology , Vascular Diseases/etiology , Veins , Venous Insufficiency/diagnosis , Venous Insufficiency/epidemiology , Venous Insufficiency/therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...